What cagrilintide is and how it may support weight loss
Cagrilintide is a long‑acting analogue of amylin, a natural hormone co‑secreted with insulin. Amylin signalling helps regulate appetite, satiety and gastric emptying. By activating amylin receptors, cagrilintide is being studied for:
- stronger fullness cues and reduced hunger
- lower meal size and snacking frequency
- slower gastric emptying that can prolong satiety
Unlike GLP‑1 medicines (such as semaglutide and tirzepatide), cagrilintide targets amylin pathways. The two mechanisms appear complementary, which is why a fixed‑dose combination with semaglutide is under investigation.
What the evidence shows so far
Research to date has focused on adults with overweight or obesity. While study designs, durations and doses vary, early findings generally suggest:
- Cagrilintide alone: average weight reduction in early trials has been reported in the mid‑single to low‑double digits (approximately 8–10% from baseline in some studies), with responses varying by dose and duration.
- Cagrilintide + semaglutide (“CagriSema”): combination therapy has reported substantially greater weight loss than semaglutide alone in Phase 2 studies (around 15–17% over 32–68 weeks in published and presented data).
Interpretation tips:
- Percent loss is an average; individual responses range widely.
- Higher doses and longer durations often increase mean loss, but also tend to raise rates of gastrointestinal side effects.
- Program quality (nutrition, activity, sleep, behavioural support) influences outcomes alongside medication.
Safety profile and common side effects
Side effects reported with cagrilintide are broadly similar to other appetite‑regulating injectables and often arise during dose escalation:
- Gastrointestinal: nausea, vomiting, constipation, diarrhoea, abdominal discomfort
- Appetite: decreased appetite, early satiety, taste changes
- General: headache, fatigue, dizziness
- Injection site: redness, itching, mild pain
Cautions discussed in clinical literature include:
- Use with insulin or sulfonylureas may increase hypoglycaemia risk; medical supervision is important.
- History of severe gastrointestinal disease or pancreatitis requires careful assessment.
- Gallbladder events and heart‑rate changes are monitored across weight‑loss drug classes; long‑term amylin‑analogue data are still developing.
- Pregnancy, breastfeeding and adolescent use are not established indications.
Who it may suit and who should avoid it
In research settings, adults with obesity or overweight (often BMI ≥30, or ≥27 with weight‑related conditions) are typical participants. People who report strong hunger, frequent snacking, or difficulty with portion control are commonly interested because amylin signalling targets satiety and meal size.
People who generally should not use it include those with contraindications identified by their clinician, those who are pregnant or breastfeeding, or anyone without appropriate medical supervision. Because cagrilintide is not TGA‑approved, access is currently limited to regulated pathways.
How cagrilintide compares to GLP‑1 and newer combinations
- Cagrilintide vs semaglutide: different primary pathways (amylin vs GLP‑1). Combination therapy has reported larger average weight loss than semaglutide alone in Phase 2 research.
- Cagrilintide vs tirzepatide: tirzepatide is a dual GIP/GLP‑1 agonist with large Phase 3 datasets and approvals in multiple regions. Cagrilintide is still investigational; the mechanistic target is satiety via amylin.
- Cagrilintide vs retatrutide: retatrutide is a triple agonist (GLP‑1/GIP/glucagon) in development; both retatrutide and cagrilintide remain investigational with no Australian approvals at the time of writing.
Compare pages: Cagrilintide vs Semaglutide, Cagrilintide vs Tirzepatide, Retatrutide vs Tirzepatide.
Dosing, administration and combination questions
- Route and frequency: studied as a once‑weekly subcutaneous injection.
- Combination: often explored with weekly semaglutide in fixed‑dose development programs.
- Titration: “start low, go slow” approaches are used in trials to manage gastrointestinal effects.
- Lifestyle: nutrition, movement, sleep and behavioural support remain essential to sustain results.
Detailed explainers: Cagrilintide Dosage Guide, Results Timeline, How to read reviews.
Access and legality in Australia
Cagrilintide is not approved by the TGA for general prescribing at this time. Access pathways are typically limited to clinical trials or regulated unapproved‑medicine routes where a doctor applies through the TGA (for example, the Special Access Scheme), and where lawful sourcing is possible.
Be cautious with any website or social listing claiming to “ship cagrilintide” as a research chemical or cosmetic. Importation and supply of prescription‑only or unapproved medicines without proper authorisation can breach Australian law and risk border seizure or unsafe products.
Next steps:
Frequently asked questions
Is cagrilintide available in Australia?
It is not TGA‑approved for routine prescribing. Access is generally limited to clinical trials or regulated unapproved‑medicine pathways managed by a doctor. See: Is Cagrilintide Legal in Australia?
How does cagrilintide cause weight loss?
It activates amylin receptors, enhancing satiety, reducing hunger and meal size, and slowing gastric emptying. This can decrease calorie intake over time.
Is cagrilintide better than semaglutide?
They work through different pathways. Early studies suggest the combination (often called “CagriSema”) can outperform semaglutide alone. Whether it is “better” for you depends on eligibility, tolerance, goals and medical advice. Compare: Cagrilintide vs Semaglutide.
What side effects should I expect?
Common effects include nausea, vomiting, constipation or diarrhoea, and decreased appetite—often most noticeable during dose escalation. See the side effects guide.
How long until results are noticeable?
Appetite changes can appear within weeks. Meaningful weight changes accumulate over months, with averages in studies typically reported at 3–12+ months. Details: Results Timeline.
Can I combine it with tirzepatide?
Combination data to date are primarily with semaglutide. Any off‑protocol combinations require individual medical assessment and may not be available or appropriate.
Is it suitable if I have type 2 diabetes?
Trials include participants with and without diabetes, but suitability is individual. If combined with insulin or insulin secretagogues, hypoglycaemia risk needs management by a clinician.
Is it legal to buy cagrilintide online and import it?
Buying unapproved medicines from overseas without authorisation is risky and may be unlawful, with seizure risk at the border. Read: Buy Cagrilintide Australia.
Does cagrilintide curb cravings or just reduce appetite?
Participants commonly report stronger satiety and reduced hunger. Some also report fewer cravings, but responses vary and behavioural support remains important.
Where can I get personalised advice?
Use the form below to ask an Australian clinician about eligibility, safety and legal access pathways.
Key takeaways
- Cagrilintide targets amylin receptors to increase satiety and reduce hunger.
- Early studies suggest meaningful weight loss, with the cagrilintide + semaglutide combination reporting larger average reductions than semaglutide alone.
- Gastrointestinal side effects are common during titration; long‑term data are still developing.
- In Australia, cagrilintide is not approved for routine prescribing. Access is limited to trials or regulated unapproved‑medicine pathways.
Ask a clinician about weight‑loss options in Australia
We provide independent information and help you understand legal pathways. We do not sell medication. If this is an emergency, call 000.
Prefer to browse? Explore the Weight Loss Injections Australia guide.